Novartis has been serving patients in Indonesia for more than 50 years, through our predecessor companies, Ciba and Sandoz.

Ianalumab prolonged the duration of safe platelet levels during and after treatment in patients with primary immune thrombocytopenia (ITP) previously treated with corticosteroids1,2 Patients treated ...

Novartis is honored to receive numerous awards for progress in research and development, our working environment, and our corporate responsibility activities.

Explore opportunities with Novartis and Sandoz below. For additional roles with Novartis Gene Therapies (formerly AveXis) visit the GTx Career Search ...

Under the leadership of Vasant Narasimhan, the Executive Committee of Novartis (ECN) is responsible for overseeing the company's business operations.

Learn what cell and gene therapy is, how it differs from conventional medicine, and why it's creating a new turning point in how we treat disease.

The Novartis Singapore site is their first biologics production facility in Asia and one of the largest biologics manufacturing investments in Singapore. It is aimed to launch and produce innovative ...

We are an innovative medicines company with research and development at our core. Our R&D engine powers an industry-leading pipeline focused on delivering transformative medicines to fight disease, ...

Sickle Cell Disease (SCD) is an inherited blood disorder that affects almost eight million 1 people worldwide, causing tremendous suffering. It’s a life-threatening condition with chronic ...

Η Novartis συνεργάζεται με την κοινότητα των ασθενών σε όλο τον κόσμο για να ανακαλύψει νέους τρόπους βελτίωσης και παράτασης της ζωής των ανθρώπων.

Improving our environmental footprint contributes to mitigating the impacts of climate change on the planet and on human health. It also allows us to increase the efficiency of our operations. As such ...

Novartis Chief Digital Officer, Bertrand Bodson and Microsoft Healthcare Corporate Vice President, Peter Lee also discussed the potential of data science and AI during a recent visit to Novartis ...